Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial

References

• McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003 [J]. J Virol. 2004;78(23):1–10. doi:10.1128/JVI.78.23.12817-12828.2004.
   PubMed Web of Science ®Google Scholar
• Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany [J]. BMC Infect Dis. 2014;14(1). doi:10.1186/1471-2334-14-365.
   Google Scholar
• Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, Petitjean A, Dibarboure H, Lopez JG. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis [J]. Hum Vaccin Immunother. 2022;1–10. doi:10.1080/21645515.2022.2050653.
   Web of Science ®Google Scholar
• Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older [J]. N Engl J Med. 2017;376(25):2427–36. doi:10.1056/NEJMoa1608862.
   PubMed Web of Science ®Google Scholar
• Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial [J]. Vaccine. 2015;33(21):2485–92. doi:10.1016/j.vaccine.2015.03.065.
   PubMed Web of Science ®Google Scholar
• Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang L-M, Chiu C-H, Chen P-Y, Ahonen A. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: a phase III randomized controlled study [J]. Hum Vaccin Immunother. 2016;12(12):3072–78. doi:10.1080/21645515.2016.1212143.
   PubMed Web of Science ®Google Scholar
• Thiem VD, Chabanon AL, Fournier M, Lavis N, Quang ND, Ha VH, Sanicas M. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older [J]. Hum Vaccin Immunother. 2021;17(3):690–93. doi:10.1080/21645515.2020.1795477.
   PubMed Web of Science ®Google Scholar
• Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, et al. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study [J]. Hum Vaccines Immunother. 2022;18(1):1–9.
   Google Scholar
• NMPA. Influenza vaccine (split virion). Inactivated; 2021 [accessed Jul 7].http://app1.nmpa.gov.cn/data_nmpa/face3/base.jsp?tableId=25&tableName=TABLE25&title=%E5%9B%BD%E4%BA%A7%E8%8D%AF%E5%93%81&bcId=152904713761213296322795806604&CbSlDlH0=qAk7racmf3Kmf3KmfKJzH8SG.zGAeIHwe4nC9ZxjqRZqqEV.
   Google Scholar
• Bart S, Cannon K, Herrington D, Mills R, Forleo-Neto E, Lindert K, Abdul Mateen A. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a phase III, double-blind, multicenter, randomized, non-inferiority study [J]. Hum Vaccin Immunother. 2016;12(9):2278–88. doi:10.1080/21645515.2016.1182270.
   PubMed Web of Science ®Google Scholar
• Moa AM, Chughtai AA, Muscatello DJ, Turner RM, Macintyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials [J]. Vaccine. 2016;34(35):4092–102. doi:10.1016/j.vaccine.2016.06.064.
   PubMed Web of Science ®Google Scholar
• Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Hum Vaccin Immunother. 2018;14(3):587–92. doi:10.1080/21645515.2017.1381808.
   PubMed Web of Science ®Google Scholar
• Basu I, Agarwal M, Shah V, Shukla V, Naik S, Supe PD, Srivastava MK, Giriraja KV, Pinjar P, Mishra PK. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - a phase III, active-controlled, randomized clinical study [J]. Hum Vaccin Immunother. 2022;18(1):1–10. doi:10.1080/21645515.2021.1885278.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, Karron RA, Walter EB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63:691–97.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults [J]. Vaccine. 2015;33(9):1151–59. doi:10.1016/j.vaccine.2015.01.025.
   PubMed Web of Science ®Google Scholar
• Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine [J]. Vaccine. 2012;30(11):1993–98. doi:10.1016/j.vaccine.2011.12.098.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults [J]. Vaccine. 2013;31(5):770–76. doi:10.1016/j.vaccine.2012.11.074.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Talbot HK, Decker MD. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older [J]. Hum Vaccin Immunother. 2017;13(9):2058–64. doi:10.1080/21645515.2017.1344375.
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial [J]. Vaccine. 2014;32(13):1480–87. doi:10.1016/j.vaccine.2014.01.022.
   PubMed Web of Science ®Google Scholar
• Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015 [J]. Vaccine. 2016;34(22):2507–12. doi:10.1016/j.vaccine.2016.03.048.
   PubMed Web of Science ®Google Scholar